Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
61 results about "HDAC6" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Histone deacetylase 6 is an enzyme that in humans is encoded by the HDAC6 gene.
3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors
ActiveUS20160304462A1Useful in treatmentImproved profileNervous disorderOrganic chemistryProliferative diseaseAutoimmune disease
The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
Owner:VALO HEALTH INC
3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
ActiveUS20160222028A1Useful in treatmentOrganic active ingredientsNervous disorderDiseaseHydroxamic acid
![3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/b31837b1-af5c-47fc-b00f-34bbda87ea97/US20160222028A1-20160804-C00001.PNG "3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors")
![3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/b31837b1-af5c-47fc-b00f-34bbda87ea97/US20160222028A1-20160804-C00002.PNG "3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors")
![3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/b31837b1-af5c-47fc-b00f-34bbda87ea97/US20160222028A1-20160804-C00003.PNG "3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors")
Owner:VALO HEALTH INC
![3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/386a7737-e24b-423f-80c4-039885e4580e/US20160221972A1-20160804-C00001.PNG "3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors")
![3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/386a7737-e24b-423f-80c4-039885e4580e/US20160221972A1-20160804-C00002.PNG "3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors")
![3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/386a7737-e24b-423f-80c4-039885e4580e/US20160221972A1-20160804-C00003.PNG "3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors")
Histone deacetylase 6 (HDAC6) biomarkers in multiple myeloma
InactiveUS20150176076A1Effective treatmentOrganic active ingredientsBiocideDrug specific IgEBiomarker (petroleum)
The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker RNAs for multiple myeloma. The invention also relates to a kit for determining the treatment efficiency of a HDAC6 inhibitor, and a kit for identifying a histone deacetylase 6 (HDAC6) inhibitor. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject.
Owner:ACETYLON PHARMA
Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
The present invention relates to pyrimidine hydroxy amide compounds, the use of such compounds in the inhibition of HDAC6, and the use of such compounds in the treatment of various diseases, disorders, or conditions related to HDAC6.
Owner:ACETYLON PHARMA
3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.
Owner:MERCK SHARP & DOHME LLC
2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
ActiveUS20200121655A1Improved profileOrganic active ingredientsNervous disorderAutoimmune conditionHydroxamic acid
The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
Owner:VALO HEALTH INC
Metalloenzyme inhibitor compounds
ActiveUS20180256572A1Improved pharmacokinetic profileOrganic active ingredientsOrganic chemistryDiseaseMedicine
Owner:EIKONIZO THERAPEUTICS INC
2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
ActiveUS10555935B2Improved profileOrganic active ingredientsNervous disorderAutoimmune conditionHydroxamic acid
Owner:VALO HEALTH INC
Application of inhibitor of histone deacetylase HDAC 6 in preparing drugs for preventing and treating acute kidney injury
InactiveCN107158390AProtective structureProtective functionOrganic active ingredientsUrinary disorderInflammatory factorsAkt signalling
The invention provides an application of inhibitor of histone deacetylase HDAC 6 in preparing drugs for preventing and treating acute kidney injury. Furthermore, the histone deacetylase HDAC 6 is Tubastatin A. The selective inhibitor of HDAC 6 can lighten the renal pathology damage of acute kidney injury induced by cis-platinum and improve the kidney function. The HDAC6 inhibitor TA can lower the release of inflammatory factors and lighten the oxidative stress reaction through regulating an AKT signal access, an NF-KB inflammation access, an autophagy level and an E-cadherin expression; thus the apoptosis of kidney tubule cell and necrosis of tubule expansion are reduced, the renal pathology damage and kidney function are improved; the inhibitor can protect the kidney structure and function in the acute kidney injury. Therefore, HDAC6 is likely to be an important target point to prevent and treat the acute kidney injury.
Owner:SHANGHAI EAST HOSPITAL
HDAC6 selective inhibitors, preparation method therefor, and application thereof
ActiveUS10745389B2Remarkable in vitro activityRemarkable effectOrganic chemistryBoron compound active ingredientsDiseaseHDAC6
Owner:CSTONE PHARM (SUZHOU) CO LTD +2
1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
ActiveUS10464911B2Prevent goodConvenient treatmentNervous disorderOrganic chemistryNervous systemNeoplasm
Owner:CHONG KUN DANG PHARMA CORP
1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
Owner:CHONG KUN DANG PHARMA CORP
Hydroxamic acid compound and application thereof
ActiveCN114315754APrevent proliferationProliferation inhibitory effect is significantOrganic chemistryAntineoplastic agentsCancer preventionHydroxamic acid
The invention relates to the field of medical chemistry, in particular to a hydroxamic acid compound containing substituted 2-phenylthiazole-5-formamide or 2-phenylimidazole-5-formamide and application of the hydroxamic acid compound, the compound has a structure as shown in a formula (I), can selectively act on HDAC6, inhibit cancer cell proliferation and enhance tumor immunity, and can be used for preparing an HDAC6 drug or an HDAC6 drug or an HDAC6 drug or an HDAC6 drug or an HDAC6 drug or an HDAC6 drug or an HDAC6 drug. The compound has efficient anti-cancer activity. Therefore, the compound can be used for preparing histone deacetylase inhibitors and drugs for treating and / or preventing cancers.
Owner:SOUTHERN MEDICAL UNIVERSITY
1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
Owner:CHONG KUN DANG PHARMA CORP
Methods for nucleic acid transfer into cells
Owner:NORTHWESTERN UNIV
Histone deacetylase 6 (HDAC6) biomarkers in multiple myeloma
InactiveUS20200405716A1Organic active ingredientsMicrobiological testing/measurementDrug specific IgEHDAC6
Owner:ACETYLON PHARMA
Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching
InactiveUS20210077487A1Effectively inhibiting and treating itchingOrganic active ingredientsDermatological disorderHDAC6Pharmaceutical drug
The present invention relates to a pharmaceutical composition containing an HDAC6 inhibitor as an active ingredient for prevention or treatment of itching. The present invention provides a novel pharmaceutical composition containing, as an active ingredient, an inhibitor for inhibiting an HDAC6 enzyme, and thus can effectively inhibit and treat itching caused by trypsin, tryptase, histamine, antimycin A, chloroquine, or the like.
Owner:BNH RES CO LTD
Biomarkers for prognosis
InactiveUS20160069887A1Increased susceptibilityLower Level RequirementsMicrobiological testing/measurementDisease diagnosisHDAC6Cell survival
The invention relates to biomarkers for determining the prognosis of cancer patients. By determining the level of the biomarker HR23B in the cell or patient, and optionally determining the levels of one or more of the biomarkers HDAC6, LC3 and HSP90, the invention provides a method for determining the susceptibility of a cell or a patient of interest to entering an autophagocytic state upon treatment with a drug. The invention also provides a method of determining susceptibility of a cell or patient to treatment with a drug. Entering an autophagocytic state is thought to be a tumour cell survival mechanism, whereby the tumour cell avoids apoptosis. The methods of the invention may therefore be helpful for determining whether a patient should be treated and for determining the prognosis upon drug treatment.
Owner:OXFORD UNIV INNOVATION LTD
Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
ActiveUS20170096405A1Prevent goodConvenient treatmentOrganic active ingredientsNervous disorderAutoimmune conditionMedicine
The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.
Owner:CHONG KUN DANG PHARMA CORP
Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
ActiveUS10287255B2Prevent goodConvenient treatmentOrganic active ingredientsNervous disorderImmunologic disordersAutoimmune condition
A compound of formula (I), having histone deacetylase 6 (HDAC6) inhibitory activity,wherein X, Q, N, R1, R2, L, and n are as described, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.
Owner:CHONG KUN DANG PHARMA CORP
Selective HDAC6 inhibitors and uses thereof
The present invention relates to selective Histone deacetylase 6 (HDAC6) inhibitors and compositions containing the same. Methods of treating diseases and conditions wherein inhibition of HDAC6 provides a benefit, like a cell proliferative disease, an autoimmune or inflammatory disorder, a neurodegenerative disease, or a combination thereof, also are disclosed.
Owner:UNIV GENT
Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs
ActiveUS11311540B2High expressionEasy to identifyOrganic active ingredientsAntineoplastic agentsCancer cellOncology
Owner:ACETYLON PHARMA
Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
ActiveUS10494355B2Prevent goodConvenient treatmentOrganic active ingredientsSenses disorderNervous systemNeoplasm
Owner:CHONG KUN DANG PHARMA CORP
1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
The invention relates to compounds of Formula (I) as described herein, useful as histone deacetylase 6 (HDAC6) inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy.
Owner:ORYZON GENOMICS SA
Double-target inhibitor as well as preparation method and application thereof
ActiveCN109761898AUnsatisfactory treatment effectHigh inhibitory activityOrganic active ingredientsOrganic chemistryElectronTumor cells
The invention discloses a double-target inhibitor as well as a preparation method and application thereof. The double-target inhibitor has a structure shown as a formula (I), wherein R1 is H, an electron-withdrawing group or an electron-donating group; R is alkyl; n is equal to 1 to 5. The double-target inhibitor provided by the invention can be used for selectively inhibiting HDAC6 and IC50 values on HDAC1 and HDAC8 are greater than 20 muM; the double-target inhibitor is used as a prodrug to be subjected to hydrolysis reaction in cells, and tubulin and an HDAC double-target inhibitor can be released; the inhibition activity of histone deacetylase on solid tumors is improved; the double-target inhibitor has a relatively good inhibition effect on tumor cells. The formula (I) is shown in thedescription.
Owner:QINGDAO UNIV
Methods and compositions for nucleic acid transfer into cells
InactiveUS20090069266A1Increase the gapIncrease gene expressionOrganic active ingredientsDrug compositionsHDAC6Gene transfer
The present invention provides compositions and methods for increasing the transfer of nucleic acids into cells. In particular, the present invention provides for the use of inhibitors of HDAC6, a cytoplasmic histone deacetylase present in mammalian cells by, for example, small molecules or siRNA treatment, in increasing gene transfer and / or expression in cells in vitro and in vivo for research and gene therapy applications.
Owner:NORTHWESTERN UNIV
Tricyclic compound and application thereof
PendingCN113121527ANovel structurePrevent proliferationOrganic active ingredientsOrganic chemistryHDAC6Pharmaceutical medicine
The invention discloses a tricyclic compound and application thereof. The invention specifically discloses a compound as shown in a formula I or pharmaceutically acceptable salt thereof. The tricyclic compound disclosed by the invention has a very good inhibition effect on HDAC (histone deacetylase), especially HDAC6, has relatively good selectivity and can be used for inhibiting proliferation of various tumor cells.
Owner:SHANGHAI LITEDD CO LTD +1
New treatment for neurodegenerative diseases
InactiveUS20150184154A1Strong responseDecreasing autophagyHydrolasesGenetic material ingredientsMedicineHDAC6
The present application provides a method for treating a neurodegenerative disease in a subject characterised in that a therapeutically effective amount of a modulator of HDAC6 administered to said subject.
Owner:NOVARTIS FORSCHUNGSSTIFTUNG
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com